ArticleAmerican journal of cancer research2020

The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET.

Danlei Yu et al.PubMed ↗Full text ↗

No numbers read from the abstract.